Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Primary sclerosing cholangitis laboratory findings

Introduction

Overview

Overview

The workup in patients with primary sclerosing cholangitis consists of LFTs, serum immunoglobulins, as well as a number of autoantibodies. Patients with primary sclerosing cholangitis typically have an elevated level of ALP, amongst other findings. However, laboratory results in many patients may be normal.

Laboratory Findings

Laboratory Findings

The workup in patients with primary sclerosing cholangitis consists of LFTs, serum immunoglobulins, as well as a number of autoantibodies. Patients with primary sclerosing cholangitis typically have an elevated level of ALP, amongst other findings. However, laboratory results in many patients may be normal.[1][2][3][4][5][6]

Liver Function Tests

Primary sclerosing cholangitis typically has a cholestatic clinical picture with elevation of ALP, and aminotransferases (AST and ALT) may be elevated to 2-3 times of the upper normal level. However, LFTs may be normal.

Immunoglobulins

Autoantibodies and Serology

One or more of the following autoantibodies may be present in patients with primary sclerosing cholangitis:

References

References

  1. ↑ Lazaridis KN, LaRusso NF (2016). “Primary Sclerosing Cholangitis”. N. Engl. J. Med. 375 (12): 1161–70. doi:10.1056/NEJMra1506330. PMID 27653566.
  2. ↑ Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ (2010). “Diagnosis and management of primary sclerosing cholangitis”. Hepatology. 51 (2): 660–78. doi:10.1002/hep.23294. PMID 20101749.
  3. ↑ Lee YM, Kaplan MM (1995). “Primary sclerosing cholangitis”. N. Engl. J. Med. 332 (14): 924–33. doi:10.1056/NEJM199504063321406. PMID 7877651.
  4. ↑ Angulo P, Peter JB, Gershwin ME, DeSotel CK, Shoenfeld Y, Ahmed AE, Lindor KD (2000). “Serum autoantibodies in patients with primary sclerosing cholangitis”. J. Hepatol. 32 (2): 182–7. PMID 10707856.
  5. ↑ Mendes FD, Jorgensen R, Keach J, Katzmann JA, Smyrk T, Donlinger J, Chari S, Lindor KD (2006). “Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis”. Am. J. Gastroenterol. 101 (9): 2070–5. doi:10.1111/j.1572-0241.2006.00772.x. PMID 16879434.
  6. ↑ Hirano K, Kawabe T, Yamamoto N, Nakai Y, Sasahira N, Tsujino T, Toda N, Isayama H, Tada M, Omata M (2006). “Serum IgG4 concentrations in pancreatic and biliary diseases”. Clin. Chim. Acta. 367 (1–2): 181–4. doi:10.1016/j.cca.2005.11.031. PMID 16426597.

Template:WikiDoc Sources

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dima Nimri, M.D. [2]